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What is already known about this subject {#bcp13876-sec-0105}
========================================

Under‐representation of elderly in clinical trials has been described earlier, thereby challenging the external validity of benefit/risk assessments of launched drugs.Pharmacokinetic differences in the elderly may give rise to differences in safety and efficacy. Therefore, it is pivotal include geriatric patients in clinical trials of medical substances.

What this study adds {#bcp13876-sec-0006}
====================

This is the first cross sectional, structured research on availability of pharmacokinetic, safety and efficacy analyses of the publicly available initial approval documents of Food and Drug Administration‐approved drugs.For the majority of the drugs, the initial approval documents showed information on pharmacokinetics in elderly, but information on safety and efficacy was missing.

1. INTRODUCTION {#bcp13876-sec-0007}
===============

The elderly represent a fast‐growing majority of the population in the Netherlands and worldwide.[1](#bcp13876-bib-0001){ref-type="ref"}, [2](#bcp13876-bib-0002){ref-type="ref"} In Europe, 25% of the population is aged 60 years or over and is expected to grow to 35% in 2050.[3](#bcp13876-bib-0003){ref-type="ref"} Importantly, the representation of older people in clinical drug trials requires special attention, as it is known that pharmacokinetics and pharmacodynamics (and hence efficacy and safety) substantially change after the age of 75 years; albeit, not all drugs are similarly affected leading to increased variability in drug levels.[4](#bcp13876-bib-0004){ref-type="ref"} In literature, different physiological parameters are discussed to affect absorption, distribution, metabolism and excretion of drugs during aging. For example, sarcopenia and increased percentage of fat tissue results in a different distribution volume.[5](#bcp13876-bib-0005){ref-type="ref"} With regard to metabolism, the total liver mass reduces with age and there is a lower capacity for phase 1 reactions through the cytochrome P‐450 enzymes.[6](#bcp13876-bib-0006){ref-type="ref"}, [7](#bcp13876-bib-0007){ref-type="ref"} In contrast, conjugation reactions are not affected by ageing.[5](#bcp13876-bib-0005){ref-type="ref"} Also, the hepatic blood flow is lower, which results in a reduced first pass effect.[8](#bcp13876-bib-0008){ref-type="ref"} The renal function diminishes with age: there is reduced renal blood flow, diminished glomerular filtration rate and a reduced renal tubular secretory function.[5](#bcp13876-bib-0005){ref-type="ref"} It is generally accepted that of the pharmacokinetic parameters, absorption is least affected by age.[5](#bcp13876-bib-0005){ref-type="ref"} Pharmacodynamic changes in the elderly are the consequence of diminished reserve capacity or diseases of organ systems and changes in receptor number and affinity.[5](#bcp13876-bib-0005){ref-type="ref"} In addition, comorbidity associated polypharmacy is more common among elderly and consequently the risk of interactions as well as adverse drug reactions is higher.[9](#bcp13876-bib-0009){ref-type="ref"} These age‐related differences may give rise to age‐specific risk/benefit ratios for drugs in elderly.

The elderly consume the majority of prescribed medications and carry the largest burden of chronic diseases.[10](#bcp13876-bib-0010){ref-type="ref"} Their representation in clinical trials should reflect this. For this reason, in 1993, the International Conference on Harmonization (ICH) of technical requirements for registration of pharmaceuticals for human use issued the ICH E7 guideline for the carrying out of studies in the geriatric population, stating that the trial population should represent the population that will consume the drug and should include a minimum percentage of older participants. The ICH E7 guideline was endorsed, among others, by the Food and Drug Administration (FDA) and pharmaceutical companies.[11](#bcp13876-bib-0011){ref-type="ref"} Nevertheless, previous reports described that elderly are generally under‐represented in clinical studies in cardiology[12](#bcp13876-bib-0012){ref-type="ref"}, [13](#bcp13876-bib-0013){ref-type="ref"}, [14](#bcp13876-bib-0014){ref-type="ref"}, [15](#bcp13876-bib-0015){ref-type="ref"}, [16](#bcp13876-bib-0016){ref-type="ref"}, [17](#bcp13876-bib-0017){ref-type="ref"} and oncology[18](#bcp13876-bib-0018){ref-type="ref"}, [19](#bcp13876-bib-0019){ref-type="ref"}, [20](#bcp13876-bib-0020){ref-type="ref"}, [21](#bcp13876-bib-0021){ref-type="ref"} as they are excluded due to older age, multimorbidity or polypharmacy. Descriptive studies showed that in 30--40% of the original research papers in major medical journals, elderly people were excluded without justification.[22](#bcp13876-bib-0022){ref-type="ref"}, [23](#bcp13876-bib-0023){ref-type="ref"} Recent investigations carried out to evaluate the adherence to the ICH E7 guideline, showed that the proportion of the elderly in clinical trials is unacceptably low (1--9% in trials involving diseases not unique to old age).[24](#bcp13876-bib-0024){ref-type="ref"} This was confirmed by an evaluation of the clinical trial database ([clinicaltrials.gov](http://clinicaltrials.gov)).[25](#bcp13876-bib-0025){ref-type="ref"} However, no investigation has systematically reviewed the available information on publicly available database of health care regulators.

In this study, we aimed to evaluate the availability of pharmacokinetic, safety and efficacy analyses specifically targeted at the elderly, prior to the authorization of the most frequently prescribed drug classes during the past years.

2. METHODS {#bcp13876-sec-0008}
==========

2.1. Design {#bcp13876-sec-0009}
-----------

A cross‐sectional, structured assessment of publicly available initial approval documents of FDA‐approved drugs was performed. To obtain marketing authorization for newly developed drugs, companies are required to deliver quality, safety and efficacy information about the drug.

2.2. Drugs of interest {#bcp13876-sec-0010}
----------------------

The following initial approval documents were assessed: those of frequently on‐label prescribed drug classes, those of drugs with known pharmacokinetic differences in the elderly, or those of drugs that are relatively contraindicated in elderly (e.g. anticholinergics or benzodiazepines). The following most frequently described drug classes were selected: antihypertensive drugs, medication for pain, drugs used for mental health or nervous system disorders, antibacterial drugs, lipid regulators, glucose lowering drugs, respiratory drugs, antiulcer drugs and thyroid therapies based on IQVIA.[26](#bcp13876-bib-0026){ref-type="ref"} Furthermore, drugs with known large or small volumes of distribution and/or high or low hepatic clearance or renal excretion were included.[4](#bcp13876-bib-0004){ref-type="ref"} Last, drugs with relative contraindications in elderly (e.g. anticholinergics or benzodiazepines).[27](#bcp13876-bib-0027){ref-type="ref"}

2.3. Assessment of information on pharmacokinetics, safety and efficacy {#bcp13876-sec-0011}
-----------------------------------------------------------------------

For these drug classes all available medical substances were extracted in December 2017 from the World Health Organization Anatomical Therapeutical Chemical Classification (ATC) index 2018.[28](#bcp13876-bib-0028){ref-type="ref"} All drugs selected for the analyses were included in Table [S1](#bcp13876-supitem-0001){ref-type="supplementary-material"}. Subsequently, using the FDA drug database, initial approval documents were retrieved for all selected drugs[29](#bcp13876-bib-0029){ref-type="ref"} during the period December 2017--March 2018. When initial approval documents were available, these were evaluated for availability of data on pharmacokinetics, efficacy and safety analyses. The availability of analyses in the geriatric population was assessed as sufficient or insufficient, based on thorough assessment of the complete initial approval document. Information was deemed sufficient if information on pharmacokinetics, efficacy and safety was present in adequate numbers (e.g. representative of the target population). *Adequate* was assessed in concordance with the ICH7 guideline: "geriatric patients should be included in the Phase 3 database (and in Phase 2, at the sponsor\'s option) in meaningful numbers." With regard to pharmacokinetic studies it is stated in the ICH7 guideline that "a pilot trial of limited size conducted under steady‐state conditions to look for sizable differences between older and younger subjects or patients" can be performed and "a larger, single‐dose pharmacokinetic study of sufficient size to permit statistical comparisons between geriatric and younger subjects' or patients\' pharmacokinetic profiles is also acceptable." A pharmacokinetic screening approach as described in the ICH7 guideline was also deemed adequate.

Furthermore, the year of initial marketing approval was extracted. One researcher (Ri.R.) performed the inclusion and assessments. In case of uncertainty, a second researcher (Ro.R.) was consulted. A random sample of 10% (*n* = 18) was selected and double checked by the second researcher (Ro.R.), to ensure correct assessment of adequateness. Outcomes were numbers (%) of initial approval documents that contained adequate data on pharmacokinetics, efficacy and safety analyses.

2.4. Statistical analyses {#bcp13876-sec-0012}
-------------------------

To assess whether the percentage of available initial approval documents significantly increased during a certain time frame, χ^2^ test statistics were used, considering *P* \< .05 statistically significant. Analyses were performed using SPSS statistics version 23.

3. RESULTS {#bcp13876-sec-0013}
==========

In the ATC database, 1129 unique active pharmaceutical ingredients were found for the analyses (Table [S1](#bcp13876-supitem-0001){ref-type="supplementary-material"}). Of these, 506 medical substances were found in the FDA database (45%). The majority consisted of drugs for mental health or nervous system disorders (*n* = 132; 26%); followed by antibacterial drugs (*n* = 101; 20%) and respiratory drugs (*n* = 86; 17%). Seventy‐one antihypertensive drugs were found (14%) and 39 glucose‐lowering drugs (8%). All other drugs each comprised \<5% of the total amount of drugs found in the FDA database **(**Figure [1](#bcp13876-fig-0001){ref-type="fig"} **)**.

![Flow diagram of the availability of initial approval documents in the Food and Drug Administration (FDA) database. WHO, World Health Organization](BCP-85-838-g001){#bcp13876-fig-0001}

Of the 506 medical substances, 182 (36%) initial approval documents were available (Table [1](#bcp13876-tbl-0001){ref-type="table"}). Of these, the majority were drugs for mental health or nervous system disorders (*n* = 51; 28%); followed by glucose‐lowering drugs (*n* = 32; 18%) and antibacterial drugs (*n* = 22; 12%). Twenty‐one antihypertensive drugs were found (12%), 16 lipid‐lowering drugs (9%) and 15 respiratory drugs (8%). Antiulcer drugs comprised 7% (*n* = 13) and all other drugs each comprised \<5% of the total amount.

###### 

Overview of the 182 substances included in the analyses (sorted on ATC code)

  **Number**   **ATC code**   **Generic product**
  ------------ -------------- -------------------------------------
  1            A02BA01        Cimetidine
  2            A02BA02        Ranitidine
  3            A02BA03        Famotidine
  4            A02BA04        Nizatidine
  5            A02BB01        Misoprostol
  6            A02BC01        Omeprazole
  7            A02BC02        Pantoprazole
  8            A02BC03        Lansoprazole
  9            A02BC04        Rabeprazole
  10           A02BC05        Esomeprazole
  11           A02BC06        Dexlansoprazole
  12           A02BX02        Sucralfate
  13           A02BX05        Bismuth subcitrate
  14           A10AB01        Insulin (inhalation)
  15           A10AB02        Insulin (glargine)
  16           A10AB03        Insulin (inhalation)
  17           A10AB06        Insulin glulisine
  18           A10AD04        Insulin lispro
  19           A10AD06        Insulin degludec and insulin aspart
  20           A10AE04        Insulin glargine
  21           A10AE05        Insulin detemir
  22           A10AE06        Insulin degludec
  23           A10BA02        Metformin
  24           A10BB02        Chlorpropamide
  25           A10BB07        Glipizide
  26           A10BB12        Glimepiride
  27           A10BF01        Acarbose
  28           A10BG01        Troglitazone
  29           A10BG02        Rosiglitazone
  30           A10BG03        Pioglitazone
  31           A10BH01        Sitagliptin
  32           A10BH03        Saxagliptin
  33           A10BH04        Alogliptin
  34           A10BH05        Linagliptin
  35           A10BJ01        Exenatide
  36           A10BJ02        Liraglutide
  37           A10BJ03        Lixisenatide
  38           A10BJ04        Albiglutide
  39           A10BJ05        Dulaglutide
  40           A10BJ06        Semaglutide
  41           A10BK01        Dapagliflozin
  42           A10BK02        Canagliflozin
  43           A10BK03        Empagliflozin
  44           A10BX03        Nateglinide
  45           A10BX05        Pramlintide
  46           C03DA04        Eplerenone
  47           C03XA01        Tolvaptan
  48           C03XA02        Conivaptan
  49           C04AB01        Phentolamine
  50           C07AB09        Esmolol
  51           C07AB12        Nebivolol
  52           C07AG02        Carvedilol
  53           C08CA01        Amlodipine
  54           C08CA02        Felodipine
  55           C08CA03        Isradipine
  56           C08CA16        Clevidipine
  57           C09AA02        Enalapril
  58           C09AA03        Lisinopril
  59           C09AA10        Trandolapril
  60           C09AA13        Moexipril
  61           C09CA02        Eprosartan
  62           C09CA03        Valsartan
  63           C09CA04        Irbesartan
  64           C09CA06        Candesartan
  65           C09CA07        Telmisartan
  66           C09CA08        Olmesartan medoxomil
  67           C09CA09        Azilsartan medoxomil
  68           C09XA02        Aliskiren
  69           C10AA01        Simvastatin
  70           C10AA02        Lovastatin
  71           C10AA03        Pravastatin
  72           C10AA04        Fluvastatin
  73           C10AA05        Atorvastatin
  74           C10AA06        Cerivastatin
  75           C10AA07        Rosuvastatin
  76           C10AA08        Pitavastatin
  77           C10AB05        Fenofibrate
  78           C10AB11        Choline fenofibrate
  79           C10AC04        Colesevelam
  80           C10AX09        Ezetimibe
  81           C10AX11        Mipomersen
  82           C10AX12        Lomitapide
  83           C10AX13        Evolocumab
  84           C10AX14        Alirocumab
  85           G04BD07        Tolterodine
  86           H03AA01        Levothyroxine sodium
  87           J01AA12        Tigecycline
  88           J01DD15        Cefdinir
  89           J01DD16        Cefditoren
  90           J01DE01        Cefepime
  91           J01DH02        Meropenem
  92           J01DH03        Ertapenem
  93           J01DH04        Doripenem
  94           J01DI02        Ceftaroline fosamil
  95           J01FA13        Dirithromycin
  96           J01FA15        Telithromycin
  97           J01MA12        Levofloxacin
  98           J01MA13        Trovafloxacin
  99           J01MA14        Moxifloxacin
  100          J01MA15        Gemifloxacin
  101          J01MA16        Gatifloxacin
  102          J01XA03        Telavancin
  103          J01XA04        Dalbavancin
  104          J01XA05        Oritavancin
  105          J01XD02        Tinidazole
  106          J01XX08        Linezolid
  107          J01XX09        Daptomycin
  108          J01XX11        Tedizolid
  109          M01AH01        Celecoxib
  110          N02AA05        Oxycodone
  111          N02AB03        Fentanyl
  112          N02AX06        Tapentadol
  113          N02BG08        Ziconotide
  114          N02CC02        Naratriptan
  115          N02CC03        Zolmitriptan
  116          N02CC04        Rizatriptan
  117          N02CC05        Almotriptan
  118          N02CC06        Eletriptan
  119          N02CC07        Frovatriptan
  120          N03AF02        Oxcarbazepine
  121          N03AF03        Rufinamide
  122          N03AF04        Eslicarbazepine
  123          N03AG04        Vigabatrin
  124          N03AG06        Tiagabine
  125          N03AX11        Topiramate
  126          N03AX14        Levetiracetam
  127          N03AX15        Zonisamide
  128          N03AX16        Pregabalin
  129          N03AX18        Lacosamide
  130          N03AX22        Perampanel
  131          N03AX23        Brivaracetam
  132          N04 BC04       Ropinirole
  133          N04 BC05       Pramipexole
  134          N04 BC06       Cabergoline
  135          N04 BC07       Apomorphine
  136          N04 BC09       Rotigotine
  137          N04BD02        Rasagiline
  138          N04BD03        Safinamide
  139          N04BX01        Tolcapone
  140          N04BX02        Entacapone
  141          N05AE04        Ziprasidone
  142          N05AE05        Lurasidone
  143          N05AH03        Olanzapine
  144          N05AH04        Quetiapine
  145          N05AH05        Asenapine
  146          N05AX08        Risperidone
  147          N05AX12        Aripiprazole
  148          N05AX13        Paliperidone
  149          N05AX14        Iloperidone
  150          N05AX15        Cariprazine
  151          N05AX16        Brexpiprazole
  152          N05AX17        Pimavanserin
  153          N05BA09        Clobazam
  154          N05CF02        Zolpidem
  155          N05CF03        Zaleplon
  156          N05CF04        Eszopiclone
  157          N05CH02        Ramelteon
  158          N05CH03        Tasimelteon
  159          N05CM18        Dexmedetomidine
  160          N05CM19        Suvorexant
  161          N06AB04        Citalopram
  162          N06AB10        Escitalopram
  163          N06AX17        Milnacipran
  164          N06AX21        Duloxetine
  165          N06AX23        Desvenlafaxine
  166          N06AX24        Vilazodone
  167          N06AX26        Vortioxetine
  168          R01AA04        Phenylephrine
  169          R01AD13        Ciclesonide
  170          R03AC13        Formoterol
  171          R03AC18        Indacaterol
  172          R03AC19        Olodaterol
  173          R03BB04        Tiotropium bromide
  174          R03BB05        Aclidinium bromide
  175          R03BB07        Umeclidinium bromide
  176          R03DC03        Montelukast
  177          R03DX05        Omalizumab
  178          R06AX17        Ketotifen
  179          R06AX24        Epinastine
  180          R06AX27        Desloratadine
  181          R07AX01        Nitric oxide
  182          R07AX02        Ivacaftor

For the majority of the drugs, the initial approval documents in the database did show information on pharmacokinetics in elderly (*n* = 113; 62%). For 1 drug, it was explicitly stated that information on pharmacokinetics, safety and efficacy in elderly was not applicable (ivacaftor). Furthermore, over time, the availability of information on pharmacokinetics in elderly increased statistically significantly from zero in the period 1979--1979 to 76% (*n* = 32) in the period 2010--2018 (*p* = .02; Table [2](#bcp13876-tbl-0002){ref-type="table"}). For safety and efficacy information in elderly, detailed information was present in respectively 77 and 81 documents (42% and 45%). In addition, the availability of information on safety and efficacy in elderly did not improve over time (*p* = 0.13 and 0.11, respectively).

###### 

Availability of information on pharmacokinetics, safety or efficacy with regard to elderly in the initial approval documents in the Food and Drug Administration database for the 10 most frequently prescribed drug classes, drugs with known large or small volumes of distribution, and/or high or low hepatic clearance or renal excretion, or which are relatively contraindicated in elderly per time period

                                                                               **Before 1950**   **1950--1959**   **1960--1969**   **1970--1979**   **1980--1989**   **1990--1999**   **2000--2009**   **2010 onwards**   **Total**
  ---------------------------------------------------------------------------- ----------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ------------------ -----------
  Number of available initial approval documents                               0                 1                0                2                9                59               69               42                 182
  Information on pharmacokinetics with regard to elderly sufficient, *n* (%)   NA                0 (0)            NA               0 (0)            1 (11)           36 (61)          44 (64)          32 (76)            113 (62)
  Information on safety with regard to elderly sufficient, *n* (%)             NA                1 (100)          NA               0 (0)            4 (44)           19 (32)          30 (43)          23 (55)            77 (42)
  Information on efficacy with regard to elderly sufficient, *n* (%)           NA                1 (100)          NA               0 (0)            4 (44)           20 (34)          32 (46)          24 (57)            81 (45)

NA, not available.

4. DISCUSSION {#bcp13876-sec-0014}
=============

In this study the availability of pharmacokinetic, safety and efficacy analyses specifically targeted at the elderly, prior to the authorization of the most frequently prescribed drug classes was evaluated. Based on the available initial approval documents, it was concluded that 62% of the FDA documents included reports on pharmacokinetic analyses, and 42 and 45% on safety and efficacy analyses in the elderly. For the majority of the drugs, the initial approval documents were not available in the database; however, over time, the percentage of available initial approval documents, as well as the information on pharmacokinetics increased significantly. With regard to crucial data on safety and efficacy, presence of information specifically on elderly was insufficient and did not increase over time.

Our results are in line with earlier studies on under‐representation of the elderly in (pre‐authorization) trials and published reports.[12](#bcp13876-bib-0012){ref-type="ref"}, [13](#bcp13876-bib-0013){ref-type="ref"}, [18](#bcp13876-bib-0018){ref-type="ref"}, [22](#bcp13876-bib-0022){ref-type="ref"}, [23](#bcp13876-bib-0023){ref-type="ref"}, [24](#bcp13876-bib-0024){ref-type="ref"}, [25](#bcp13876-bib-0025){ref-type="ref"} It was reported that only 3 of the 155 clinical trials on 4 widely prescribed drugs were exclusively designed for patients aged 65 years and older.[30](#bcp13876-bib-0030){ref-type="ref"} Moreover, a recent assessment of all performed clinical trials in 2012 revealed that only 2% of the randomized controlled trials were designed for elderly aged 65 and over.[31](#bcp13876-bib-0031){ref-type="ref"}

Unfortunately, we have shown that despite efforts to include elderly patients in clinical drug trials, under‐representation of elderly patients is still present, which challenges the external validity of benefit/risk assessments of launched drugs and leads to the phenomenon of off label prescribing in old patients.[32](#bcp13876-bib-0032){ref-type="ref"} With regard to elderly, adequate representation of the targeted population in clinical trials is of pivotal importance as pharmacokinetic differences may give rise to differences in safety and efficacy. However, there are differences in opinion on this issue between EU countries leading to differences in clinical trial regulations and practice in older people, further complicating the adequate inclusion of elderly in clinical trials.[16](#bcp13876-bib-0016){ref-type="ref"} Efforts have been made to overcome the underrepresentation of the elderly in clinical research. The updated ICH E7 guideline emphasizes the need for additional short‐ and long‐term safety data, adapted age‐specific endpoints and subjective outcomes such as quality of life. Moreover, the population under research should reflect the population at which the drug under investigation is aimed. Unfortunately, no specific percentage can be given as the percentage of elderly in the target population differs per drug. Nevertheless, efforts should be made to include patients aged \>80 years with different degrees of comorbidity and frailty.[33](#bcp13876-bib-0033){ref-type="ref"} For example, it was recommended to include older people in phase 1 clinical trials on gynaecological cancers, as they have similar toxicity profiles compared to their younger counterpart.[34](#bcp13876-bib-0034){ref-type="ref"} However, including elderly in clinical trials remains challenging: given the presence of protocol restrictions (e.g. exclusion criteria on age, polypharmacy and multimorbidity), many elderly must be screened before 1 study participant can be enrolled.[30](#bcp13876-bib-0030){ref-type="ref"}

One of the major drawbacks of this study is that it could not be verified which specific older patients in terms of age, ethnicity, sex and comorbidities were included in the clinical trials. This is important as the elderly population included in the assessed initial approval documents could have consisted of relatively healthy elderly with 1 disease, thus not being representative of the target population of elderly which the drugs are using namely those elderly with multiple comorbidities and polypharmacy.[33](#bcp13876-bib-0033){ref-type="ref"} Furthermore, the presence of information on pharmacokinetic studies could only be quantitatively assessed and not qualitatively. The available information was highly variable per assessed molecular entity; for example, different definitions of *elderly* were used, and information on *numbers* of elderly in clinical trials was missing frequently. As noticed in the methods section, the ICH7 guideline was used to deem whether numbers of included elderly were adequate, a random sample (10%) of the assessed reports was double checked to verify correct assessment of adequateness. Also, pages of the assessed initial approval reports were regularly withdrawn for confidentiality reasons of the submitting company. Furthermore, there is no way to determine whether all data submitted to the FDA are available in the online published documents. Lastly, not all pharmaceutical ingredients were found as drugs in the FDA database, which probably leads to nondifferential misclassification.

To our knowledge, this is the first study to assess the presence of information on pharmacokinetics, safety and efficacy in initial approval documents accessible in the FDA database. During the period 1927--2013, a total of 1453 drugs obtained FDA approval and the FDA still approves dozens of drugs each year.[35](#bcp13876-bib-0035){ref-type="ref"} However, an analysis on the availability of pre‐authorization information on pharmacokinetics, safety and efficacy in elderly in the FDA database has not yet been performed. In a methodological guideline on the use of FDA documents for evidence syntheses, the benefit of using aggregated clinical trial information from FDA documents for the interpretation of data was emphasized, as it is less biased than published trial information.[36](#bcp13876-bib-0036){ref-type="ref"} Nevertheless, since 2010, there is still insufficient data available on safety and efficacy of the most frequently prescribed drugs in the elderly. Knowing that older people account for the majority of all drug consumers, priority should be given to clinical research with a study population that is representative for the actual patient population.[10](#bcp13876-bib-0010){ref-type="ref"}
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